• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    津

    津山中央病院

    Tsuyama Chuo Hospital
    EST. 1954
    520论文总数
    8,576引用总数

    论文量&引用量时间轴

    机构学者

    论文(520)

    年份
    起
    –
    止
    排序
    1Model-Based Normal Tissue Complication Probability Comparison Between Proton and Photon Therapies for Brain Tumors Complying with Planning Study Guidelines
    Hajime Higaki,Kentaro Nishioka,Kohei Yokokawa, Keiji Nakazato, Izuru Otake,Keiji Kobashi, Atsushi Motegi,Hideyuki Sakurai,Masao Murakami,Hiroyasu Tamamura,Takahiro Waki,Takashi Ogino,

    Purpose The benefit of proton beam therapy (PBT) for primary brain tumors compared with x-ray therapy has not been demonstrated by randomized controlled trials. We performed a model-based approach study to evaluate the potential benefit of PBT for brain tumors using the normal tissue complication probability (NTCP) models complying with the Radiotherapy Treatment plannINg study Guidelines (RATING). Methods and Materials Sixty-six patients with primary brain tumors treated with PBT were registered. We used 11 NTCP models, calculated NTCP for each adverse event, and estimated the PBT and intensity modulated radiation therapy (IMRT) plans for the entire patient population and for groups classified by pathology. Wilcoxon signed-rank tests were performed for statistically significant differences between the 2 modalities, and a 2-tailed test was considered significant when <.05. A reduction was considered clinically meaningful when the difference in NTCP between the 2 modalities (ΔNTCP) exceeded the prespecified threshold. Results Overall, PBT reduced NTCP from the cataracts, delayed recall, memory impairment, contralateral hearing impairment, and tinnitus. Patients with meningiomas and low-grade gliomas had similar tendencies. PBT was associated with a lower excess absolute risk of secondary cancer of the central nervous system in all patients. However, NTCPs for alopecia, blindness, and brain necrosis were higher in the PBT cohort, highlighting important clinical trade-offs. Thirty-one patients (47.0%) had at least 1 ΔNTCP above the specified threshold. Conclusions In this model-based planning comparison, PBT was associated with lower estimated NTCPs for selected endpoints compared with virtual IMRT, whereas IMRT showed advantages for alopecia, blindness, and brain necrosis. PBT may offer meaningful clinical benefits, particularly in reducing the excess absolute risk of secondary cancer for patients with long-term survival. In addition, the comparison based on Radiotherapy Treatment plannINg study Guidelines made the study more objective than similar previous studies.

    2027Advances in Radiation Oncology(2027)
    引用
    AI阅读
    加入学术空间
    2Prospective Registry and Meta-Analysis of Particle Therapy for Hepatocellular Carcinoma: Clinical Outcomes and Real-World Impact.
    Masashi Mizumoto,Kei Shibuya,Kazuki Terashima,Hiromitsu Iwata, Takashi Saito,Shingo Toyama,Takashi Ogino,Masao Murakami,Tatsuya Ohno,Yoshitaka Sato,Tetsuo Akimoto,Hiroyuki Katoh,

    BACKGROUND AND AIMS:This study aimed to evaluate the clinical efficacy of particle therapy for hepatocellular carcinoma (HCC) by integrating a prospective registry and a systematic meta-analysis. Our findings also reflect the real-world impact of this evidence, which contributed to the national health insurance approval of particle therapy for HCC tumors ≥ 4 cm in Japan. METHODS:Patients who received particle therapy for HCC from May 2016 to June 2018 were registered. Ninety studies (25 particle therapy, 26 non-SBRT, 36 SBRT, 3 studies reporting multiple modalities) were selected. RESULTS:A total of 836 cases (proton beam therapy 576, carbon therapy 260) were examined. The median overall survival (OS) was 53.7 months (95% CI 47.4-NA). The 1-, 2-, 3- and 4-year OS rates were 85.2% (95% CI 82.6%-87.4%), 71.4% (68.1%-74.4%), 60.5% (56.9%-63.9%), and 53.5% (49.1%-57.7%), respectively; and the 1-, 2-, 3- and 4-year local recurrence rates were 3.5% (2.1%-4.9%), 8.8% (6.3%-10.8%), 12.0% (9.3%-14.8%), and 13.6% (10.5%-16.7%), respectively. In the meta-analysis and registry data, the 1-, 2-, and 3-year OS rates of particle therapy and SBRT for small HCC (< 4 cm) were 90.0%/87.7% (p = 0.4788), 75.3%/73.6% (p = 0.6724), and 62.8%/63.5% (p = 0.9771), respectively; and the 1-, 2-, and 3-year OS rates of particle therapy, SBRT and non-SBRT for large HCC (≥ 4 cm) were 81.1%/62.0% (p = 0.0032)/66.8% (p = 0.0021), 65.4%/38.1% (p = 0.0001)/38.4% (p = 0.0001), and 50.4%/31.8% (p = 0.0001)/25.9% (p = 0.0001), respectively. CONCLUSIONS:A prospective registry study and meta-analysis indicated that particle therapy is a better treatment modality than SBRT for large HCC. Particle therapy and SBRT gave similar outcomes for small HCC. These findings contributed to the adoption of particle therapy for tumors ≥ 4 cm under Japan's national health insurance, highlighting its real-world impact.

    2026Cancer medicine(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Predictive Nomogram for Recurrence after Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2)
    Ryuichi Yoshida,Kosei Takagi,Kazuya Yasui,Masayoshi Hioki,Takehiro Okabayashi,Toru Kojima,Yoshikatsu Endo,Daisuke Nobuoka,Kenta Sui,Masaru Inagaki, Susumu Shinoura,Masashi Kimura,

    Background/Objectives: Postoperative recurrence is a critical issue in the treatment of resectable pancreatic ductal adenocarcinoma (rPDAC). Moreover, the prognosis after early recurrence is extremely poor. This study aimed to develop a recurrence prediction model and to define early recurrence after upfront surgery (UFS) for rPDAC. Methods: This multicenter retrospective study included patients who underwent UFS for anatomically rPDAC between January 2013 and December 2017. Multivariate analyses were conducted to identify the risk factors for recurrence-free survival and to construct a recurrence prediction model. Subsequently, a minimum p value approach was used to determine the optimal cutoff values for early and late recurrence. Results: The cohort included 603 patients (325 men and 278 women). During the median follow-up period of 25 months (interquartile range, 15-38 months), 381 patients (63.2%) experienced a recurrence. Multivariate analyses revealed carbohydrate antigen 19-9 ≥37 U/mL (hazard ratio [HR], 1.58; p < 0.001), tumor size ≥ 2.2 cm (HR, 1.59; p < 0.001), lymph node metastasis (HR, 1.86; p < 0.001), R1 resection (HR, 1.56; p = 0.002), and no adjuvant chemotherapy (HR, 1.54; p < 0.001) as independent predictors. The recurrence prediction model demonstrated an area under the curve of 0.72-0.75. The optimal threshold for early and late recurrences was a recurrence-free interval of five months. Carbohydrate antigen 19-9 ≥ 156 U/mL was a significant predictor of early recurrence (OR, 3.28; p < 0.001). Conclusions: This study identified the prognostic risk factors for recurrence and developed a recurrence prediction model for patients undergoing UFS for rPDAC. Moreover, a recurrence-free interval of five months was identified as the optimal threshold for distinguishing between early and late recurrences.

    2026Cancers(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Factors Associated with Technical Difficulty in Endoscopic Submucosal Dissection for Undifferentiated Early Gastric Cancer: Post Hoc Analysis of JCOG1009/1010
    Tomohiro Mitsui,Kohei Takizawa,Tomohiro Kadota,Gakuto Ogawa,Hiroyuki Ono,Noriaki Hasuike,Ryu Ishihara,Toshiyuki Yoshio,Tsuneo Oyama,Daisuke Kikuchi,Yasuhiro Inokuchi,Yosuke Toya,

    Endoscopic submucosal dissection (ESD) is a minimally-invasive curative treatment for early gastric cancer (EGC). Recently, JCOG1009/1010, a multicenter, prospective, single-arm, confirmatory trial, showed that of ESD for undifferentiated early gastric cancer (UD-EGC) ≤ 2 cm without ulceration are comparable with those of gastrectomy, resulting in the expansion of the indications of ESD for UD-EGC. Herein, we explored the factors associated with technical difficulty in ESD in patients with UD-EGC using data from JCOG1009/1010. The inclusion criteria for JCOG1009/1010 were histologically proven undifferentiated-type adenocarcinoma, cT1aN0M0, absence of ulceration, and tumor size of < 2 cm. The technically difficult cases were defined as those with an ESD procedure time of > 120 min, intraoperative perforation, or incomplete en bloc resection. We compared difficult and non-difficult ESD cases and performed multivariable analysis. Of 346 patients enrolled in JCOG1009/1010, 332 were analyzed. Technical difficulties were experienced in 70 (21

    2026Surgical Endoscopy(2026)
    引用
    AI阅读
    加入学术空间
    5A MODEL-BASED APPROACH FOR MEDIASTINAL TUMORS; ANALYSIS OF NATIONAL REGISTRY -INTERIM ANALYSIS-
    Hideyuki Harada,Masatoshi Nakamura, Yutaro Mori,Atsushi Motegi,Tetsuo Akimoto,Hiromitsu Iwata,Masanori Machida,Takashi Ogino,Masaki Nakamura,Sunao Tokumaru,Hitoshi Tatebe,Takahiro Waki,
    2026International Journal of Particle Therapy(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 520 篇论文

    合作机构(100)

    岡山大学合作论文 122
    千叶大学合作论文 73
    冈山大学医院合作论文 53
    岡山済生会総合病院合作论文 30
    倉敷中央病院合作论文 29
    Mthatha General Hospital合作论文 27
    Kagawa Prefectural Central Hospital合作论文 26
    福山市民病院合作论文 24
    日本大学合作论文 20
    东京女子医科大学合作论文 19

    机构统计